Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

• Randy Hecht,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Yue-Sheng Li,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Jeonghoon Sun,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Ed Belouski,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Michael Hall,

  Affiliation Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Todd Hager,

  Affiliation Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Junming Yie,

  Affiliation Departments of Metabolic Disorders, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Wei Wang,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Dwight Winters,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Stephen Smith,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Chris Spahr,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Lei-Ting Tam,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Zhongnan Shen,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Shanaka Stanislaus,

  Affiliation Departments of Metabolic Disorders, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Narumol Chinookoswong,

  Affiliation Departments of Metabolic Disorders, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Yvonne Lau,

  Affiliation Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Allen Sickmier,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Mark Leo Michaels,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Thomas Boone,

  Affiliation Department of Protein Sciences, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Murielle M. Véniant,

  Affiliation Departments of Metabolic Disorders, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
•  [ ... ],
• Jing Xu

  * E-mail: jingx@amgen.com

  Affiliation Departments of Metabolic Disorders, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• [ view all ]
• [ view less ]